Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Abstract Metastatic non-small-cell lung cancer (NSCLC) with activating EGFR mutations responds very well to first and second generation tyrosine-kinase inhibitors (TKI) including gefitinib, erlotinib and afatinib. Unfortunately, drug resistance will eventually develop and about half of the cases are...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2017
|
| Subjects: | |
| Online Access: | https://doaj.org/article/48baaceb101f44bbbb0e692bec36675e |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!